PARP1 and colorectal carcinoma: This observation may reveal another opportunity to elucidate whether anti-VEGF/EGFR-resistant CRC cells may be sensitized by agents, such as PARP inhibitors or the novel agents targeting the ATR-CHK1-WEE1 axis [269].